See All Slides - tctmd.com

Slides

Presentation TCT 2013

Case #1: An Isolated Ostial/Mid-shaft Left Main Lesion

Presenter: Patrick Whitlow

October 31, 2013

Presentation TCT 2013

Can Basal Modalities Ever Be as Good as Hyperemic Indices?

Presenter: Nils Johnson

October 31, 2013

Presentation TCT 2013

Getting Started in a University Practice: What To Do and What Not To Do

Presenter: Robert Yeh

October 31, 2013

Presentation TCT 2013

How Would I Treat this Patient?(7)

Presenter: George Latsios

October 31, 2013

Presentation TCT 2013

Indigenous Stents: New Technologies and Clinical Data

Presenter: Sreenivas Kumar

October 31, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

Presentation TCT 2013

Stroke Syndromes and Diagnosis

Presenter: Wade Smith

October 31, 2013

Presentation TCT 2013

AV Fistula-Graft Application: Biological Rationale, Technical Approach, and Early Data

Presenter: Karnabatidis Dimitrios

October 31, 2013

Presentation

Acute vs. Chronic Antithrombotic Management in ACS: Need for a Paradigm Shift?

Presenter: Gregg Stone

October 31, 2013

Advertisement

Slides

Case #1: An Isolated Ostial/Mid-shaft Left Main Lesion

Can Basal Modalities Ever Be as Good as Hyperemic Indices?

Getting Started in a University Practice: What To Do and What Not To Do

How Would I Treat this Patient?(7)

Indigenous Stents: New Technologies and Clinical Data

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Stroke Syndromes and Diagnosis

AV Fistula-Graft Application: Biological Rationale, Technical Approach, and Early Data

Acute vs. Chronic Antithrombotic Management in ACS: Need for a Paradigm Shift?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content